Evgen Pharma Share Discussion Threads

[markth126] 07/12/2021 07:40

It takes time as we know to develop these things but looks like they have a good bit of that with a lot of plates spinning all of which still sound like they are progressing. I do wonder what Kight is playing at adding all of the time but time will tell i guess

[amaretto1] 07/12/2021 07:33

Bit harsh from me ...... but nothing we don't already no !

[amaretto1] 07/12/2021 07:25

About the only positive i can see.

[markth126] 07/12/2021 07:09

10M remaining in cash with market cap of 14m, I'm very enthused about that as that is a 3 year run way of cash at the current burn rate really. Add in Huws comments about looking forward a successful to a second half - I'm a happy holder this morning.

[moneymunch] 07/12/2021 07:01

RNS Number : 7347U
Evgen Pharma PLC
07 December 2021






Evgen Pharma plc

("Evgen" or "the Company" or "the Group")



Half year Report



Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2021.



Operational highlights

· Malignant glioma Orphan Drug Designation for SFX-01 granted by FDA

· Encouraging early in vitro data for SFX-01 in Juvenile Myelomonocytic Leukaemia ("JMML") at the MRC Weatherall Institute, University of Oxford

· Final preclinical work in glioblastoma (''GBM'') completed and in late-stage preparation for a Phase Ib/II trial

· In vitro pre-clinical work supports SFX-01 use in metastatic breast cancer patients who have become resistant to the widely-used class of CDK4/6 inhibitor drugs

· Publication of positive preclinical in vitro and in vivo data in GBM from two independent groups of collaborators in Italy and New Zealand

· Scale-up of the active ingredient in SFX-01 to commercial scale achieved with a number of process improvements

· New formulation of SFX-01 generated in tablet form enabling scale up to supply late-stage clinical trials and commercial use

· Dr Helen Kuhlman and Dr Glen Clack appointed as Chief Business Officer and Chief Medical Officer respectively, completing the senior management team





Financial highlights

· Financial performance in-line with expectations:

o Post-tax loss of £1.5m (2020: loss of £1.8m)

o Cash outflow from operations of £1.5m (2020: outflow of £1.9m)

o Cash deposits, cash and cash equivalents balance at 30 September 2021 of £10.1m (30 September 2020: £2.3m)



Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "The last six months has yielded further positive preclinical data to support the potential of SFX-01 in a number of cancers and an Orphan Drug Designation in the USA for malignant glioma. With the scale up and refinement of the SFX-01 production process and design of the Phase I and Phase II clinical trials running in parallel, we look forward to commencing further important clinical programmes in H1 2022. With our strengthened senior management team that brings further expertise, we look forward to a successful second half of the year and I would like to extend my thanks to our shareholders for their continued support."

[markth126] 06/12/2021 17:04

Would be a nice thought but somehow doubt that! He can have mine for 12p!

[on target] 06/12/2021 16:02

Being dragged down on nothing now.
Come on Kight, make your 15-20p/share bid and put us out of our misery.

[moneymunch] 03/12/2021 15:30

News on Monday prior to results would be apt.....got a game of golf booked so every chance. Gla ;-)

[lovewinshatelosses] 03/12/2021 14:48

I thought you were being sarcastic OT; did not see the sudden flurry of decent level buying! Splendid.

[david gruen] 03/12/2021 14:41

We're off to the races

[lovewinshatelosses] 03/12/2021 14:32

Last of the big spenders.... :)

[on target] 03/12/2021 14:31

Our buyer's in town.

[lovewinshatelosses] 03/12/2021 13:52

Cannot argue with that statement. Nevertheless, bought another 10K shares. GLA.

[amaretto1] 03/12/2021 09:50

SP is laughable

[mrwizard1] 02/12/2021 17:28

Radio silence. Last PR highlighted the same old uninteresting in vitro and in vivo studies. No mention of any business development activity. What is CBO doing? What is Kight's interest that he now owns 10%. Company seems like an annuity policy for management and board. In short, a hot mess.

[abbynat] 02/12/2021 16:07

16.06 and not one solitary trade! mm,mm.

[markth126] 01/12/2021 19:47

Calm before the storm?

[lovewinshatelosses] 26/11/2021 08:57

As am I, Mark. Nobody who is invested here is unaware of the potential risks, but I have read the last few RNS's with increasing degrees of optimism. I would like to have seen some decent inside buying before now. More marketing/podcasts/interviews etc to try and get the name out to a wider audience and keep us more on the radar during waiting periods for material news. Therefore some criticism still justified for now, IMO and has given some ammunition to the bears.
The potential upside far outweighs the potential downside IMO; certainly some opportunity cost along the way so far for me, but it is not sunk cost fallacy that keeps me here. Right or wrong, not long to find out hopefully. GLA.

[markth126] 25/11/2021 22:48

Or a success and off we go !! I'm holding on and believe. Remember octopus ? were in at 8p keep the faith! They must know the craic so to speak!!

[amaretto1] 25/11/2021 16:41

Lol ...clown !

[kingalf] 25/11/2021 13:39

Could surprise us all and announce they've had a bid approach from our friend Kight. Before anyone gets too excited I can't see it much above 8.25p. Failing that, it will be the usual cash burn rate and how super excited they are about future prospects.

[moneymunch] 25/11/2021 08:12

Some news before the Results would be timely. Gla ;-)

[lovewinshatelosses] 23/11/2021 16:18

Well, either the bored sellers will be kicking themselves, or they will be patting themselves on the back. No in between on this one I suspect! Feels like I should have waited for 5's again now. Ready to do so again, if and when. GLA.

[moneymunch] 23/11/2021 07:02

RNS Number : 1731T
Evgen Pharma PLC
23 November 2021


Evgen Pharma plc

("Evgen Pharma" or "the Company")



Notice of results



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces it will issue its unaudited interim results for the six months ended 30 September 2021 on Tuesday, 7 December 2021.

[on target] 22/11/2021 14:35

Dripping down again on bored sellers.

Come on Huw give us an update - has the pre-IND meeting happened yet or have you even made the appointment?